QC
BLTE

Quadrature Capital’s Belite Bio BLTE Stock Holding History

Quadrature Capital’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.78M Sell
23,708
-1,124
-5% -$189K 0.05% 270
2025
Q4 		$3.97M Buy
24,832
+21,002
+548% +$2.49M 0.04% 253
2025
Q3 		$283K Buy
+3,830
New +$251K ﹤0.01% 685

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quadrature Capital's BLTE Position: Q1 2026 in Review

Quadrature Capital reduced its Belite Bio (BLTE) stake by 4.5% in Q1 2026, selling an estimated $189K and leaving 23,708 shares worth $3.78M. The position accounts for 0.05% of the portfolio, ranked #270.

Quadrature Capital first reported a position in BLTE in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.97M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Quadrature Capital held 23,708 shares of Belite Bio worth $3.78M as of Q1 2026.
  • Quadrature Capital sold 1,124 Belite Bio shares in Q1 2026, an estimated $189K.
  • Belite Bio made up 0.05% of Quadrature Capital's portfolio in Q1 2026, its #270 holding.
  • Quadrature Capital first reported a position in Belite Bio in Q3 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Belite Bio position peaked at $3.97M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.